Risk prediction model for overall survival in lung cancer based on inflammatory and nutritional markers
Abstract
Abstract This study aims to develop a multidimensional risk prediction model, identify characteristic inflammation-nutrition biomarkers, and optimize clinical decision-making. The study included 500 lung cancer patients diagnosed between October 2019 and October 2024 at a tertiary medical institution in Guiyang, China. The exposure variables included eight inflammation-nutrition biomarkers: neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), hemoglobin-albumin-lymphocyte-platelet score (HALP), prognostic nutritional index (PNI), hemoglobin-to-red cell distribution width ratio (HRR), and albumin-to-globulin ratio (ALB/GLB). The outcome variable was overall survival (OS). This study aimed to predict 1-year mortality rather than conduct traditional time-to-event survival analysis. All patients were followed until death or a uniform administrative censoring point.LASSO logistic regression was employed to model the outcome as a binary classification (death within 1 year: yes/no).This study employed a small-sample modeling approach, initially using LASSO regression for feature selection and dimensionality reduction, followed by variance inflation factor and collinearity screening for secondary feature selection. Finally, the Support Vector Machine-Recursive Feature Elimination (SVM-RFE) algorithm was used to optimize feature variables. The results showed that age, clinical stage, poor differentiation, ECOG PS 0–1, serum albumin level, LMR, HRR, and ALB/GLB were independent prognostic factors. Based on these factors, a lung cancer mortality risk prediction model was developed, and a corresponding web-based calculator was created, providing a practical tool to support clinical decision-making and personalized treatment strategies.
Article Details
Authors (12)
Hongqi Zhou
Department of Chemistry, College of Science, Guangdong Provincial Key Laboratory of Catalysis, Guangming Advanced Research Institute
Weiyun Jin
Lindi Li
Xiangwen Nie
Weiwei Wu
Ran Chen
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences
Qizhen Xie
Haixia Wu
Weiwei Jiang
State Key Laboratory of Advanced Fiber Materials, College of Chemistry and Chemical Engineering
Min Tang
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Paediatrics, West China Second University Hospital, State Key Laboratory of Biotherapy, Sichuan University
Jinhai Wang
Maoyuan Wang
Department of Rehabilitation Medicine, The First Affiliated Hospital of Gannan Medical University